The ANZTCT Registry Journal Publications & Recent Presentations Journal Publications Doherty DA, ong SYC, Reilly J, Shrapnel J, McDonald S, Ahern S, Harris I, Tam CS, Brennan AL, Hodgson C, Wilcox L, Balagurunathan A, Butcher B, Reid C. Registry randomised trials: a methodological perspective. BMJ Open 2023 Moore J, Hamad N, Gottlieb DJ, Bajel A, Ritchie DS, Yeung DT, Greenwood M, Purtill D, Tran S, Solterbeck A, Aarons D, Kwan J. Early cessation of calcineurin inhibitors is feasible post haploidentical blood stem cell transplant-the ANZHIT-1 study. Blood Adv. 2023 Okamoto S, Iida M, Hamad N, Duarte FB, Sureda A, Srivastava A, Galeano S, Chao N, Rondelli D, Flowers ME; Asia-Pacific Blood and Marrow Transplantation Group (APBMT),; Australia and New Zealand Transplant and Cellular Therapy (ANZTCT),; Brazilian Society of Blood and Marrow Transplantation (SBTMO),; European Society for Blood and Marrow Transplantation (EBMT),; Indian Society for Blood and Marrow Transplantation (ISBMT),; Latin America Bone Marrow Transplantation Group (LABMT). American Society of Transplantation and Cellular Therapy International Affair Committee: Report of the Third Workshop on Global Perspective to Access to Transplantation at the 2022 Tandem Meeting. Transplant Cell Ther. 2023. Othman J, Aarons D, Bajel A, Butler J, Doocey R, O'Brien T, Purtill D, Smith L, Wilcox L, Hamad N. Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID-19 pandemic: a report from Australia and New Zealand transplant and cellular therapies. Intern Med J. 2023 Coutsouvelis J, Kirkpatrick CM, Dooley M, Spencer A, Kennedy G, Chau M, Huang G, Doocey R, Copeland TS, Do L, Bardy P, Kerridge I, Cole T, Fraser C, Perera T, Larsen SR, Mason K, O'Brien TA, Shaw PJ, Teague L, Butler A, Watson AM, Ramachandran S, Marsh J, Khan Z, Hamad N. Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study. Transplant Cell Ther. 2023 Saccardi R, Putter H, Eikema DJ, Busto MP, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FA, Baldomero H, Beguin Y, de la Cámara R, Cedillo Á, Balari AMS, Chabannon C, Corbacioglu S, Dolstra H, Duarte RF, Dulery R, Greco R, Gusi A, Hamad N, Kenyon M, Kröger N, Labopin M, Lee J, Ljungman P, Manson L, Mensil F, Milpied N, Mohty M, Oldani E, Orchard K, Passweg J, Pearce R, de Latour RP, Poirel HA, Rintala T, Rizzo JD, Ruggeri A, Sanchez-Martinez C, Sanchez-Guijo F, Sánchez-Ortega I, Trnková M, Ferreiras DV, Wilcox L, de Wreede LC, Snowden JA, Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2023 Iida M, Liu K, Huang XJ, Depei W, Kuwatsuka Y, Moon JH, Dodds A, Wilcox L, Ko BS, Hamidieh AA, Ho KW, Ungkanont A, Ho A, Farzana T, Sim J, Man HV, Akter M, Abeysinghe P, Bravo MR, Gyi AA, Poudyal BS, Batshkh K, Srivastava A, Okamoto S, Atsuta Y; Registry Committee of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT). Trends in disease indications for hematopoietic stem cell transplantation in the Asia-Pacific region: A report of the Activity Survey 2017 from APBMT. Blood Cell Ther. 2022 Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBC, Kröger N, Mohty M, Galeano S, Okamoto S, Chaudhri N, Karduss AJ, Ciceri F, Colturato VAR, Corbacioglu S, Elhaddad A, Force LM, Frutos C, León AG, Hamad N, Hamerschlak N, He N, Ho A, Huang XJ, Jacobs B, Kim HJ, Iida M, Lehmann L, de Latour RP, Percival MM, Perdomo M, Rasheed W, Schultz KR, Seber A, Ko BS, Simione AJ, Srivastava A, Szer J, Wood WA, Kodera Y, Nagler A, Snowden JA, Weisdorf D, Passweg J, Pasquini MC, Sureda A, Atsuta Y, Aljurf M, Niederwieser D. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2023 Kliman D, Tran S, Kennedy G, Curley C, McLean A, Gottlieb D, Kwan J, Ritchie D, Chee L, Spencer A, Purtill D, Bardy P, Larsen S, Chien N, Perera T, Greenwood M, Hamad N, Moore J. The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. Bone Marrow Transplant. 2022 Connolly EA, Weickhardt A, Grimison P, Asher R, Heller GZ, Lewin J, Liow E, Toner G, Tung ILY, Tran B, Hill S, Walpole E, McKenzie J, Kuchel A, Goh J, Forgeson G, Tan A, Joshi A, Wickham A, Tan H, Wang Y, Winstanley MA, Hamad N, Wong V High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres.BJU Int. 2022 Nath K, James Y, Taylor D, Gardner R, Rai N, Ware RS, Taylor K, Morton J, Durrant S, Irving I, Bashford J. Activity and outcomes of autologous stem cell transplantation in the private sector in Australia. Intern Med J. 2023 Duncan Purtill, Cheryl Hutchins, Glen Kennedy, Andrea McClean, Chris Fraser, Peter J Shaw, Paul Chiappini, Helen Tao, David Ma, Karieshma Kabani, Lijun Bai, Matthew Greenwood, Ashish Bajel, Elizabeth O’Flaherty, David Curtis, Leanne Purins, Travis Perera, Sarah Tan, Andrew Butler, Ken Micklethwaite, Vicki Antonenas, David Gottlieb, Nada Hamad. Good Engraftment but Quality and Donor Concerns for Cryopreserved HPC Products Collected During the COVID-19 Pandemic. Transplantation and Cellular Therapy 2021. Julian Lindsay, Ian Kerridge, Leonie Wilcox, Steven Tran, Tracey A. O'Brien, Matthew Greenwood, Sharon C.-A. Chen, David C.M. Kong, Steven A. Pergam, Catherine Liu, Monica A. Slavin. Infection-Related Mortality in Adults and Children Undergoing Allogeneic Hematopoietic Cell Transplantation: An Australian Registry Report. Transplantation and Cellular Therapy 2021. Nivison-Smith I, Bajel A, Dodds AJ, Gottlieb D, Hamad N, Kennedy G, Kerridge I, Ma DDF, Milliken S, Moore J, Purtill D, Szer J. Effect of donor age on adult unrelated donor hematopoietic cell transplant outcome: the Australian experience. Internal Medicine Journal 2020 (published on-line). Lwin Y, Kennedy G, Gottlieb D, Kwan, Ritchie D, Szer J, Samuel Milliken S, Browett P, Spencer A, Butler A, Bardy P, Greenwood M, Perera T, He S, McEwan A, Larsen S, Lai H, Purtill D, Tran S, Aarons D, Hamad N. Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. Biology Blood Marrow Transplantation 2020. 26: 2252-2261. Chinnabhandar V, Tran S, Sutton R, Shaw PJ, Mechinaud F, Cole C, Tapp H, Teague L, Fraser C, O'Brien TA, Mitchell R, Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) Transplantation and Cellular Therapy in Children (TACTIC). Addition of thiotepa to total body irradiation and cyclophosphamide conditioning for allogeneic hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation 2020. Jul 28;S1083-8791(20)30461-4. Jad Othman, Matthew Greenwood, John Moore, Stephen Larsen, Anne-Marie Watson, Chris Arthur, Abir Bhattacharyya, Ian Bilmon, Emily Blyth, Adam Bryant, Christian Bryant, Lindsay Dunlop, Keith Fay, John Gibson, Nada Hamad, Ian Kerridge, John Kwan, David Ma, Kenneth Micklethwaite, Samuel Milliken, Shyam Panicker, William Stevenson, Barbara Withers, Leonie Wilcox, Steven Tran, David J Gottlieb. Unrelated donor transplant recipients given Thymoglobuline have superior GRFS when compared to matched related donor recipients transplanted without ATG. Biology of Blood and Marrow Transplantation, 2020 David Kliman, Ian Nivison-Smith, David Gottlieb, Nada Hamad, Ian Kerridge, Duncan Purtill, Jeff Szer, David Ma. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation. Biology of Blood and Marrow Transplantation, 2020 Matthew J. Rees, Andrew Spencer, Peter Browett, Frank Alvaro, Duncan Purtill, Julie Crawford, Sam Milliken, Hock Lai, Humphrey Pullon, Andrew Grigg. High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission. Bone Marrow Transplant, 2020 (letter) Uden T, Bertaina A, Abrahamsson J, Ansari M, Balduzzi A, Bourquin J-P, Gerhardt C, Bierings M, Hasle H, Lankester A, Mischke K, Moore AS, Nivison‐Smith I, Pieczonka A, Peters C, Sedlacek P, Reinhardt D, Stein J, Versluys B, Wachowiak J, Willems L, Zimmermann M, Locatelli F, Sauer MG. Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I‐BFM analysis of 333 children. British Journal of Haematology 2020, Volume 189, Issue 4 (published on-line) John A. Snowden, Riccardo Saccardi, Kim Orchard, Per Ljungman, Rafael Duarte, Myriam Labopin, Carmen Ruiz de Elvira, Debra Gordon, Eoin McGrath, Nigel Brook, Hélène Antoine-Poirel, Francis Ayuk Ayuketang, Yves Beguin, Francesca Bonifazi, Christian Chabbanon, Alois Gratwohl, Noel Milpied, John Moore, Jakob Passweg, J. Doug Rizzo, Steve Spellman, Nicolaus Kroeger, Jurgen Kuball, Mohamad Mohty, Silvia Montoto, Arnon Nagler, Ibrahim Yakoub-Agha, Fermin Sanchez-Guijo, Nina Worel, Andreu Gusi, Gillian Adams, Helen Baldomero, Gilles Macq, E. Marry, Florence Mesnil, Elena Oldani, Rachel Pearce, Julia Perry, Nicole Raus, Urs Schanz, Steven Tran, Leonie Wilcox, Gzregorz Basak, Selim Corbacioglu, Harry Dolstra, Arjan Lankester, Jan Styczinski, Regis Peffault de la Tour, Theodor Balan, Ronald Brand, Liesbeth C. de Wreede, Erik van Zwet & Hein Putter. Benchmarking of Survival Outcomes following Haematopoietic Stem Cell Transplantation: A position paper on the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant, 2019. E Hamilton, K Nath, V Vangaveti, A McCutchan, J Marsh, A Birchley, J Casey, C McNamara, H Lai, E Morris, G Hodges, I Irving. A 14 year retrospective analysis of indication and outcomes of autologous haematopoietic cell transplantation in regional Queensland- a single centre experience. Intern Med J 2019. Iida M, Kodera Y, Dodds A, Ho AYL, Nivison-Smith I, Akter MR, Wu T, Lie AKW, Ghavamzadeh A, Kang HJ, Ong TC, Gyi AA, Farzana T, Baylon H, Gooneratne L, Tang JL, Bunworasate U, Huynh VM, Srivastava A, Okamoto S, Atsuta Y; Registry Committee of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT). Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005-2015. Bone Marrow Transplant. 2019;54:1973-1986. Selim A, Alvaro F, Cole CH, Fraser C, Mechinaud F, O'Brien TA, Shaw PJ, Tapp H, Teague L, Nivison-Smith I, Moore AS. Haematopoietic stem cell transplantation for children with acute myeloid leukaemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group . Pediatr Blood Cancer. 2019; Nivison-Smith I, Milliken S, Dodds A, Gottlieb D, Kwan J, Ma DDF, Shaw PJ, Tran S, Wilcox L, Szer J. Activity and capacity profile of transplant physicians and centres in Australia and New Zealand. Biol Blood and Marrow Transplant. 2018; 24:169-174. Patton WN, Nivison-Smith I, Bardy P, Dodds A, Ma DDF, Shaw PJ, Kwan J, Wilcox L, Butler A, Carter JM, Blacklock H, Szer J. Graft transit time has no effect on outcome of unrelated donor haematopoietic cell transplants performed in Australia and New Zealand: a study from the Australasian Bone Marrow Transplant Recipient Registry. Biol Blood and Marrow Transplant. 2017; 23:147-152. Nelson AS, Vajdic CM, Ashton LJ, Le Marsney RE, Nivison-Smith I, Wilcox L, Dodds AJ, O'Brien TA. Incident cancers and late mortality in Australian children treated by allogeneic stem cell transplantation for non-malignant diseases. Pediatr Blood Cancer 2017; 64:197-202. Kruger P, Cooney J, Nivison-Smith I, Bardy P, Ma D, Szer J, Durrant S. All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand. Bone Marrow Transplant. 2016;51:1400-1403. Nath CE, Trotman J, Tiley C, Presgrave P, Joshua D, Kerridge I, Kwan YL, Gurney H. McLachlan AJ, Earl JW, Nivison-Smith I, Zeng L, Shaw PJ. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. Br J Clin Pharmacol. 2016; in press Vajdic CM, Mayson E, Dodds AJ, O'Brien TA, Wilcox L, Nivison-Smith I, Le Marsney R, Daniels B, Ashton LJ, CAST study investigators. Second cancer risk and late mortality in adult Australians receiving allogeneic haematopoietic stem cell transplantation: A population-based cohort study. Biol Blood Marrow Transplant. 2016;22:949-956. Nivison-Smith I, Bardy P, Dodds AJ, Ma DD, Aarons D, Tran S, Wilcox L, Szer J. A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013. Biol Blood Marrow Transplant. 2016;22:284-291. Nelson AS, Ashton LJ, Vajdic CM, Le Marsney RE, Daniels B, Nivison-Smith I, Wilcox L, Dodds AJ, O'Brien TA. Second cancers and late mortality in Australian children treated by allogeneic HSCT for hematological malignancy. Leukemia 2014;29:441-447. Ashton LJ, Le Marsney RE, Dodds AJ, Nivison-Smith I, Wilcox L, O'Brien TA, Vajdic CM. A population-based cohort study of late mortality in adult autologous hematopoietic stem cell transplant recipients in Australia. Biol Blood Marrow Transplant 2014;20:937-945. Bilmon I, Nivison-Smith I, Hertzberg M, Ritchie D, Greenwood M, Spencer A, Kennedy G, Bryant A, Moore J. Outcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning. Bone Marrow Transplant 2014;49:852-853. (Letter) Bilmon IA, Ashton LJ, Le Marsney RE, Dodds AJ, O'Brien TA, Wilcox L, Nivison-Smith I, Daniels B, Vajdic CM and CAST study group. Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study. Bone Marrow Transplant 2014;49:691-698. Bryant A, Nivison-Smith I, Pillai ES, Kennedy G, Kalff A, Ritchie D, George B, Hertzberg M, Patil S, Spencer A, Fay K, Cannell P, Berkahn L, Doocey R, Spearing R, Moore J. Fludarabine Melphalan reduced intensity conditioning allotransplantation provides similar disease control in lymphoid and myeloid malignancies - analysis of 344 patients. Bone Marrow Transplant 2014; 49:17-23. Gordon SJ, Nivison-Smith I, Szer J, Chapman JR. Volunteer unrelated donor experience after administration of filgrastim and apheresis for the collection of haemopoietic stem cells - the Australian perspective. Intern Med J 2013;43(11):1183-1190. Mitchell R, Nivison-Smith I, Anazodo A, Tiedemann K, Shaw P, Teague L, Fraser C, Carter T, Tapp H, Alvaro F, O'Brien T. Outcomes of hematopoietic stem cell transplantation for inherited metabolic disorders: a report from Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) and the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR). Pediatr Transplant 2013;17(6):582-588. Nivison-Smith I, Simpson JM, Dodds AJ, Ma DDF, Szer J, Bradstock KF. A population-based analysis of the effect of autologous hematopoietic cell transplantation in the treatment of multiple myeloma. Leuk Lymphoma 2013;54(8):1671-1676. Mitchell R, Nivison-Smith I, Anazodo A, Tiedemann K, Shaw P, Teague L, Fraser C, Carter T, Tapp H, Alvaro F, O'Brien T. Hematopoietic stem cell transplantation outcomes in primary immunodeficiency: a report from the Australian and New Zealand Children's Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. Biol Blood Marrow Transplant 2013;19(3):338-343. Nivison-Smith I, Dodds AJ, Butler J, Bradstock KF, Ma DDF, Simpson JM, Szer J. Allogeneic hematopoietic cell transplantation for myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk. Biol Blood Marrow Transplant 2012; 18:302-308. Nivison-Smith I, Dodds AJ, Doocey R, Ganly P, Gibson J, Ma DDF, Simpson JM, Szer J, Bradstock KF. Allogeneic hematopoietic cell transplantation for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. Leuk Lymphoma 2011; 52: 1727-1735. Nivison-Smith I, Dodds AJ, Dunckley H, Ma DDF, Moore JJ, Simpson JM, Szer J, Bradstock KF. Increased activity and improved outcome in unrelated donor haemopoietic cell transplants for acute myeloid leukaemia in Australia, 1992-2005. Internal Medicine Journal 2011; 41: 27-34. Nivison-Smith I, Simpson JM, Dodds AJ, Ma DDF, Szer J, Bradstock KF. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates. Biol Blood Marrow Transplant 2009; 15: 1323 - 1330. Worthley DL, Ruszkiewicz A, Davies R, Moore S, Nivison-Smith I, To LB, Browett P, Western R, Durrant S, So J, Young GP, Mullighan CG, Bardy PG, Michael MZ. Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem Cells 2009; 27:1463-1468. Moore AS, Shaw PJ, Hallahan AR, Carter TL, Kilo T, Nivison-Smith I, O’Brien TA, Tapp H, Teague L, Wilson SR and Tiedemann K. Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children’s Haematology Oncology Group. Med J Aust 2009; 190: 121-125. Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S, Gibson J, Patton N, Bradstock K, Marks DI and G Cook on behalf of the BSBMT & ABMTRR. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007; 40: 443 - 450. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Ma DDF, Moore JJ, Simpson JM, Szer J. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007; 13: 905 - 912. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J, Durrant S, Schwarer A, Bardy P, Herrmann R, Dodds A. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13: 601-607. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Szer J. Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: A progress report from the Australasian Bone Marrow Transplant Recipient Registry. Intern Med J 2005; 35: 18-27. Nivison-Smith I, Bradstock KF, Szer J, Durrant S, Dodds A, Herrmann R, Schwarer AP, Gibson J, To LB, Arthur C. Allogeneic haemopoietic cell transplants in Australia, 1996 - a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. Bone Marrow Transplant 2001; 28:21-27. Atkinson K, Nivison-Smith I, Hawkins T Haemopoietic cell transplantation in Australia 1992-95: a report from the Australian Bone Marrow Transplant Recipient Registry. Aust NZ J Med 1997; 27: 408-419. Atkinson K, Downs K, Hawkins T. Bone marrow transplantation in Australia during 1992. Australian Bone Marrow Transplant Recipient Data Registry. Bone Marrow Transplant 1994; 13:737-739.